RCMNY
SRNE

Rubric Capital Management (New York)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Rubric Capital Management (New York)’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-447,610
Closed -$1.51M – 64
2019
Q4 		$1.51M Buy
+447,610
New +$1.07M 0.17% 46

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rubric Capital Management (New York)'s SRNE Position: Q1 2020 in Review

Rubric Capital Management (New York) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2020, closing a stake of 447,610 shares — an estimated $1.51M sold.

Rubric Capital Management (New York) first reported a position in SRNE in Q4 2019 and held it in 1 quarter. The position peaked at $1.51M in Q4 2019. 92 funds tracked by Wall St. Rank hold SRNE as of Q1 2020.

  • Rubric Capital Management (New York) reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 447,610 Sorrento Therapeutics, Inc. shares in Q1 2020, an estimated $1.51M.
  • Rubric Capital Management (New York) first reported a position in Sorrento Therapeutics, Inc. in Q4 2019 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Sorrento Therapeutics, Inc. position peaked at $1.51M in Q4 2019.
  • 92 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2020.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2020, filed 14 May 2020.